DeFinium Therapeutics Inc (DFTX)

$18.23 +1.35 (8.00%)
Market Cap 1.66B
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.31
Volume 2,055,000
Avg Vol 1,999,262
Day's Range N/A - N/A
Shares Out 98.51M
Stochastic %K 79%
Beta 2.57
Analysts Strong Sell
Price Target $29.38
ngalifi1
ngalifi1 Feb. 3 at 4:42 AM
$DFTX anyone else panicking
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Feb. 3 at 1:20 AM
$DFTX We are sued https://www.reuters.com/legal/government/lsd-therapy-biotech-definium-sued-alleged-trade-secret-theft-2026-02-02/
1 · Reply
Rocketzz
Rocketzz Feb. 2 at 11:30 PM
$DFTX
0 · Reply
AndyFromTheFuture
AndyFromTheFuture Feb. 2 at 10:28 PM
$DFTX ♾️
0 · Reply
Horseman23
Horseman23 Feb. 2 at 10:26 PM
$DFTX just wait until we get news! FDA approval, legalization! Then we fly!
0 · Reply
bgreen10
bgreen10 Feb. 2 at 10:12 PM
$DFTX to $80
0 · Reply
Invest4_life
Invest4_life Feb. 2 at 10:10 PM
$DFTX $86 sooner than later ;)
1 · Reply
BioBum
BioBum Feb. 2 at 9:54 PM
$DFTX “new employee inducement grant” email seriously once a week
0 · Reply
twiggs462
twiggs462 Feb. 2 at 8:57 PM
$DFTX Might as well make it an even 100
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 7:51 PM
$DFTX $70
0 · Reply
Latest News on DFTX
Definium Therapeutics Announces New Employee Inducement Grants

Feb 2, 2026, 4:00 PM EST - 16 hours ago

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 29, 2026, 7:00 AM EST - 5 days ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 20, 2026, 7:00 AM EST - 14 days ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 7:16 PM EST - 19 days ago

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MMED

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 13, 2026, 7:00 AM EST - 21 days ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Jan 12, 2026, 7:00 AM EST - 22 days ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:01 AM EST - 6 weeks ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

MindMed Announces New Employee Inducement Grant

Dec 15, 2025, 4:01 PM EST - 7 weeks ago

MindMed Announces New Employee Inducement Grant

MindMed Announces New Employee Inducement Grants

Dec 1, 2025, 4:01 PM EST - 2 months ago

MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:46 PM EST - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 3 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 3 months ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 3 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 3 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 3 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 3 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 3 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 4 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 4 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 5 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 5 months ago

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 6 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 6 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 6 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 8 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 9 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 9 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 9 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 9 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 10 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 10 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 11 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 11 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 11 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

ngalifi1
ngalifi1 Feb. 3 at 4:42 AM
$DFTX anyone else panicking
1 · Reply
MichaelNaussCMT
MichaelNaussCMT Feb. 3 at 1:20 AM
$DFTX We are sued https://www.reuters.com/legal/government/lsd-therapy-biotech-definium-sued-alleged-trade-secret-theft-2026-02-02/
1 · Reply
Rocketzz
Rocketzz Feb. 2 at 11:30 PM
$DFTX
0 · Reply
AndyFromTheFuture
AndyFromTheFuture Feb. 2 at 10:28 PM
$DFTX ♾️
0 · Reply
Horseman23
Horseman23 Feb. 2 at 10:26 PM
$DFTX just wait until we get news! FDA approval, legalization! Then we fly!
0 · Reply
bgreen10
bgreen10 Feb. 2 at 10:12 PM
$DFTX to $80
0 · Reply
Invest4_life
Invest4_life Feb. 2 at 10:10 PM
$DFTX $86 sooner than later ;)
1 · Reply
BioBum
BioBum Feb. 2 at 9:54 PM
$DFTX “new employee inducement grant” email seriously once a week
0 · Reply
twiggs462
twiggs462 Feb. 2 at 8:57 PM
$DFTX Might as well make it an even 100
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 7:51 PM
$DFTX $70
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Feb. 2 at 7:47 PM
$DFTX 60
0 · Reply
Horseman23
Horseman23 Feb. 2 at 7:20 PM
$DFTX gimme 50
0 · Reply
goral17
goral17 Feb. 2 at 7:11 PM
$DFTX Loaded moar...wtf is going on here!?
1 · Reply
blipper
blipper Feb. 2 at 6:41 PM
$DFTX so are we still going to Croatia?
1 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Feb. 2 at 6:23 PM
$DFTX Here comes $20.
2 · Reply
BobbyCucumber
BobbyCucumber Feb. 2 at 6:12 PM
$DFTX Check out comments on goral's 1/31 10:35am post. He attacks Rocketzz MOM!!! With sexual innuendo!!! After Rocketzz posts a rather innocuous observation. I believe we're walking on new ground here folks, although not sure, I don't give him the pleasure of reading what he posts about me, (a tenet of successful trolling), so he could be attacking my great great grandmother for all l know. Why do bears/shorts always end up going for your mom???
1 · Reply
yuuuuuppppp
yuuuuuppppp Feb. 2 at 6:00 PM
$DFTX Unfortunately, I don't think JAN2027 options will hit like I was expecting them to. Probably won't see any income until 2030.
0 · Reply
BobbyCucumber
BobbyCucumber Feb. 2 at 5:28 PM
$DFTX ..."let's hope goral is short, let's hope goral is short, let's hope goral is short........"
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 5:09 PM
$DFTX
0 · Reply
Beachlife22
Beachlife22 Feb. 2 at 4:51 PM
$DFTX https://www.biospace.com/drug-development/psychedelics-space-at-a-tipping-point-as-compass-definium-gear-up-to-file-for-approval
0 · Reply
Rocketzz
Rocketzz Feb. 2 at 4:49 PM
$DFTX goral’s puts lol
0 · Reply
Chukt22
Chukt22 Feb. 2 at 4:26 PM
$DFTX might just be the strongest 6 month chart in the entire market. Fear and rotation everywhere, not here. TATONKA.
0 · Reply